X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VP-001 is a precision therapy that aims to restore the expression of the PRPF31 gene back to levels required for the normal function of the retina, which is investigated for the treatment of retinitis pigmentosa type 11.
Lead Product(s): VP-001
Therapeutic Area: Genetic Disease Product Name: VP-001
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2023
Details:
VP-001 is the first and only treatment to demonstrate restoration of this critical barrier function in a patient-derived model.
Lead Product(s): VP-001
Therapeutic Area: Genetic Disease Product Name: VP-001
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2021
Details:
PYC's lead development candidate VP-001 is designed to deliver its therapeutic RNA cargo directly into the nuclei of retinal cells, with the goal of upregulating PRPF31 gene expression and reversing the progressive retinal degeneration and eventual blindness caused by RP11.
Lead Product(s): VP-001
Therapeutic Area: Ophthalmology Product Name: VP-001
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
